Current pricing
| Wegovy | Mounjaro | |
|---|---|---|
| Monthly range | $400–$460 | $350–$500 |
| Cheapest provider | Hub Health ($338) | Hub Health ($398) |
| Annual estimate | $4,800–5,500 | $4,200–6,000 |
| PBS prospect | Pending (BMI ≥35 + CVD) | None |
What's changed since last update
Pricing has remained relatively stable since Wegovy's launch in Australia. The main development is the pending PBS listing — if Wegovy gets subsidised, it becomes dramatically cheaper for eligible patients ($31.60 vs $400+).
Mounjaro pricing varies more between providers due to different dose strengths at different escalation stages. The range is wider ($350–500) but the ceiling is higher because maximum dose (15mg) costs more than lower maintenance doses.
Value comparison
Despite Mounjaro's wider price range, it arguably offers better value per dollar when you factor in effectiveness:
- Mounjaro: ~$5,100/year for ~21% weight loss = $243 per percentage point
- Wegovy: ~$5,000/year for ~16% weight loss = $312 per percentage point
However, if Wegovy gets PBS listed, the equation reverses entirely for eligible patients.
Our recommendation
If you qualify for PBS: wait for Wegovy's listing or start Wegovy now with plans to switch to PBS when available. If you don't qualify for PBS: Mounjaro offers more weight loss per dollar at similar monthly costs.
Full head-to-head comparison →
Provider-by-provider breakdown
Which telehealth providers offer the best pricing for each medication? We've compiled the latest data:
The key trend: subscription-based providers (Juniper, Hub Health) are competitive on total monthly cost when you factor in bundled consultations and delivery. Pay-per-consult providers (Qoctor, InstantScripts) can be cheaper if you're disciplined about filling scripts at discount pharmacies and spacing out follow-ups.
When will prices come down?
Two factors could reduce prices: PBS listing for Wegovy (pending — would drop to ~$31.60/script for eligible patients) and increased competition as more GLP-1 medications enter the market (oral semaglutide, orforglipron). Generic semaglutide is unlikely before 2030 due to patent protection. For now, comparison shopping between providers is the most effective cost-reduction strategy.